 |
|
CLINICIAN'S CORNER
Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary DiseaseA Systematic Review and Meta-analysis
Sonal Singh, MD, MPH;
Yoon K. Loke, MBBS, MD;
Curt D. Furberg, MD, PhD
JAMA. 2008;300(12):1439-1450.
Context Inhaled anticholinergics (ipratropium bromide or tiotropium bromide) are widely used in patients with chronic obstructive pulmonary disease (COPD) but their effect on the risk of cardiovascular outcomes is unknown.
Objective To ascertain the cardiovascular risks of inhaled anticholinergics, including cardiovascular death, myocardial infarction (MI), and stroke.
Data Sources Systematic searches were conducted on March 19, 2008, of relevant articles in MEDLINE, the Cochrane Database of systematic reviews, regulatory authority Web sites in the United States and the United Kingdom, and manufacturers' trial registries with no date restrictions.
Study Selection Randomized controlled trials of any inhaled anticholinergic for treatment of COPD that had at least 30 days of treatment and reported on cardiovascular events.
Data Extraction The primary outcome was a composite of cardiovascular death, MI, or stroke. The secondary outcome was all-cause mortality. Relative risks (RRs) were estimated using fixed-effects models and statistical heterogeneity was estimated with the I2 statistic.
Data Synthesis After a detailed screening of 103 articles, 17 trials enrolling 14 783 patients were analyzed. Follow-up duration ranged from 6 weeks to 5 years. Cardiovascular death, MI, or stroke occurred in 135 of 7472 patients (1.8%) receiving inhaled anticholinergics and 86 of 7311 patients (1.2%) receiving control therapy (RR, 1.58 [95% confidence interval {CI}, 1.21-2.06]; P < .001, I2 = 0%). Among individual components of the primary end point, inhaled anticholinergics significantly increased the risk of MI (RR, 1.53 [95% CI 1.05-2.23]; P = .03, I2 = 0%) and cardiovascular death (RR, 1.80 [95% CI, 1.17-2.77]; P = .008, I2 = 0%) without a statistically significant increase in the risk of stroke (RR, 1.46 [95% CI, 0.81-2.62]; P = .20, I2 = 0%). All-cause mortality was reported in 149 of the patients treated with inhaled anticholinergics (2.0%) and 115 of the control patients (1.6%) (RR, 1.26 [95% CI, 0.99-1.61]; P = .06, I2 = 2%). A sensitivity analysis restricted to 5 long-term trials (>6 months) confirmed the significantly increased risk of cardiovascular death, MI, or stroke (2.9% of patients treated with anticholinergics vs 1.8% of the control patients; RR, 1.73 [95%CI, 1.27-2.36]; P < .001, I2 = 0%).
Conclusion Inhaled anticholinergics are associated with a significantly increased risk of cardiovascular death, MI, or stroke among patients with COPD.
Author Affiliations: Department of Medicine (Dr Singh) and Division of Public Health Sciences (Dr Furberg), Wake Forest University School of Medicine, Winston-Salem, North Carolina; and School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, England (Dr Loke).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Risk of Major Adverse Cardiovascular Events With Inhaled Anticholinergics in Patients With Chronic Obstructive Pulmonary Disease
Yuji Oba
JAMA. 2009;301(12):1223.
EXTRACT
| FULL TEXT
Risk of Major Adverse Cardiovascular Events With Inhaled Anticholinergics in Patients With Chronic Obstructive Pulmonary Disease
Henry D. Covelli
JAMA. 2009;301(12):1223.
EXTRACT
| FULL TEXT
Risk of Major Adverse Cardiovascular Events With Inhaled Anticholinergics in Patients With Chronic Obstructive Pulmonary Disease
Steven Kesten, Inge Leimer, and Michele Jara
JAMA. 2009;301(12):1224.
EXTRACT
| FULL TEXT
Risk of Major Adverse Cardiovascular Events With Inhaled Anticholinergics in Patients With Chronic Obstructive Pulmonary Disease
Katherine E. Hodgin and James P. Maloney
JAMA. 2009;301(12):1224.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Safety and Pharmacokinetics of Multiple Doses of Aclidinium Bromide, a Novel Long-Acting Muscarinic Antagonist for the Treatment of Chronic Obstructive Pulmonary Disease, in Healthy Participants
Jansat et al.
J Clin Pharmacol 2009;49:1239-1246.
ABSTRACT
| FULL TEXT
How to increase the value of randomised trials in COPD research
Puhan and Schunemann
Eur Respir J 2009;34:552-558.
ABSTRACT
| FULL TEXT
Outcomes Associated With Tiotropium Use in Patients With Chronic Obstructive Pulmonary Disease
Lee et al.
Arch Intern Med 2009;169:1403-1410.
ABSTRACT
| FULL TEXT
Update in Asthma 2008
Moore
Am. J. Respir. Crit. Care Med. 2009;179:869-874.
FULL TEXT
Update in Chronic Obstructive Pulmonary Disease 2008
Maclay et al.
Am. J. Respir. Crit. Care Med. 2009;179:533-541.
FULL TEXT
Risk of Major Adverse Cardiovascular Events With Inhaled Anticholinergics in Patients With Chronic Obstructive Pulmonary Disease
Oba
JAMA 2009;301:1223-1223.
FULL TEXT
Risk of Major Adverse Cardiovascular Events With Inhaled Anticholinergics in Patients With Chronic Obstructive Pulmonary Disease
Kesten et al.
JAMA 2009;301:1224-1224.
FULL TEXT
Risk of Major Adverse Cardiovascular Events With Inhaled Anticholinergics in Patients With Chronic Obstructive Pulmonary Disease
Covelli
JAMA 2009;301:1223-1223.
FULL TEXT
Risk of Major Adverse Cardiovascular Events With Inhaled Anticholinergics in Patients With Chronic Obstructive Pulmonary Disease
Hodgin and Maloney
JAMA 2009;301:1224-1224.
FULL TEXT
How Much Did Biases in the Study of Chronic Obstructive Pulmonary Disease Medications and Mortality Affect the Outcome?
Lee et al.
ANN INTERN MED 2009;150:426-427.
FULL TEXT
From large clinical trials to management of COPD in the real world
Cazzola
Ther Adv Respir Dis 2009;3:39-46.
ABSTRACT
Tiotropium in Chronic Obstructive Pulmonary Disease
Pedone et al.
NEJM 2009;360:185-187.
FULL TEXT
All you need to read in the other general journals
BMJ 2008;337:a1854-a1854.
FULL TEXT
|
